i am/we are long luv, voo. i wrote this article myself, and it expresses my own opinions. i am not receiving compensation for it (other than from seeking alpha). i have no business relationship with any company whose stock is mentioned in this article. any material in this article shou...
This reference is of importance because takes stock of the posibility of using combination ICI and targeted drugs as neoadjuvant treatment in HCC. Akin Telli T, Bregni G, Vanhooren M, et al. Regorafenib in combination with immune checkpoint inhibitors for mismatch repair proficient (pMMR)/micro...